Does CSL (ASX:CSL) Losing TAVNEOS Authorisation Undermine Its Diversification And Regulatory Resilience Story?

Simply Wall St.07-04

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended revoking CSL Vifor’s TAVNEOS marketing authorisation in the EU, after finding manipulated and unreliable ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649691995?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","is_english":true,"pubTime":"2026-07-04 22:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649691995","market":"nz","top_or_hot":-1,"title":"Does CSL (ASX:CSL) Losing TAVNEOS Authorisation Undermine Its Diversification And Regulatory Resilience Story?","media":"Simply Wall St.","content":"<div>\n<p>The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended revoking CSL Vifor’s TAVNEOS marketing authorisation in the EU, after finding manipulated and unreliable ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsl-losing-tavneos-authorisation-undermine-its-d\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does CSL (ASX:CSL) Losing TAVNEOS Authorisation Undermine Its Diversification And Regulatory Resilience Story?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes CSL (ASX:CSL) Losing TAVNEOS Authorisation Undermine Its Diversification And Regulatory Resilience Story?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-04 22:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsl-losing-tavneos-authorisation-undermine-its-d><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended revoking CSL Vifor’s TAVNEOS marketing authorisation in the EU, after finding manipulated and unreliable ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsl-losing-tavneos-authorisation-undermine-its-d\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4086","symbol_name":"建筑产品","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsl-losing-tavneos-authorisation-undermine-its-d","article_id":"2649691995","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/does-csl-asxcsl-losing-tavneos-authorisation-undermine-its-d","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649691995","pubTimestamp":1783175140,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended revoking CSL Vifor’s TAVNEOS marketing authorisation in the EU, after finding manipulated and unreliable pivotal trial data and prompting CSL to halt new patient starts across EMA jurisdictions.\nThis setback not only raises the prospect of an impairment charge for TAVNEOS intellectual property, but also highlights how regulatory scrutiny can directly test CSL’s diversification benefits and risk...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4086":"建筑产品","CSL":"卡莱尔伙伴","BK7508":"医药生物股","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","CSL.AU":"CSL LIMITED","BK7067":"生物科技","AIPO":"Defiance AI and Power Infrastructure ETF","BK7511":"ESG概念","BK7501":"新冠治疗股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC"},"translate_title":"CSL(ASX：CSL)失去TAVNEOS授权是否会破坏其多元化和监管弹性故事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":1.5,"AIPO":0.62},"content_text":"The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended revoking CSL Vifor’s TAVNEOS marketing authorisation in the EU, after finding manipulated and unreliable pivotal trial data and prompting CSL to halt new patient starts across EMA jurisdictions. This setback not only raises the prospect of an impairment charge for TAVNEOS intellectual property, but also highlights how regulatory scrutiny can directly test CSL’s diversification benefits and risk controls. We’ll now examine how the EMA’s recommendation to withdraw TAVNEOS challenges CSL’s investment narrative built on diversification and regulatory resilience. Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.AdvertisementCSL Investment Narrative RecapTo own CSL, you need to believe that its core plasma, vaccine and nephrology franchises can offset setbacks in smaller products and support earnings recovery. On that score, the EMA move on TAVNEOS looks more like a credibility and governance test than a major earnings shock, though any impairment and loss of diversification benefits add to what is already a sensitive short term backdrop of margin pressure and cost execution risk. The TAVNEOS news lands just months after CSL’s H1 FY2026 result, where net income fell sharply to US$401m and management narrowed FY2026 revenue guidance to about US$15.2b, down around 2% on FY2025. This combination of weaker profitability, leadership transition and a fresh regulatory issue tightens the focus on near term delivery of the cost savings program and the ramp up of newer therapies like ANDEMBRY and HEMGENIX. Yet against this broad diversification story, investors still need to watch how concentrated regulatory risks in CSL Vifor may... Read the full narrative on CSL (it's free!)CSL's narrative projects $16.9 billion revenue and $3.2 billion earnings by 2029.Uncover how CSL's forecasts yield a A$138.19 fair value, a 13% upside to its current price.Exploring Other PerspectivesASX:CSL 1-Year Stock Price Chart Before this TAVNEOS setback, the most pessimistic analysts already assumed only about 2.9% annual revenue growth and earnings of roughly US$3.7b by 2029, so you can see how their more cautious view on regulatory and portfolio risks could diverge even further from consensus if this kind of issue starts to challenge assumptions about CSL Vifor’s contribution and the timing of margin improvement.Explore 13 other fair value estimates on CSL - why the stock might be worth over 2x more than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your CSL research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.Our free CSL research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CSL's overall financial health at a glance.No Opportunity In CSL?Our top stock finds are flying under the radar-for now. Get in early:Uncover the next big thing with 59 elite penny stocks that balance risk and reward.This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.AI is about to change healthcare. These 9 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649691995","isCrawlerRequest":true}